Bio-Rad outlines 2026 currency-neutral revenue growth of -3% to +0.5% amid Middle East disruption

Merck KGaAMerck KGaA Backs Hybrid Cancer Drugs And Greener Lab Consumables - simplywall.st

BioPharma DiveArvinas’ ‘Protac’ breast cancer drug cleared by FDA

Endpoints NewsModerna in talks with FDA over Phase 4 Covid vaccine data

Bio-RadBio-Rad Weighs 2026 Outlook As Middle East Headwinds Meet Stilla Hopes - simplywall.st

Endpoints NewsFDA approves Pfizer and Arvinas' breast cancer drug despite underwhelming data

ModernaModerna’s first quarter 2026 sales well ahead of estimates - The Pharma Letter

Endpoints NewsAmgen launches late-stage obesity trial in patients who switch from rival drugs

FierceBiotech‘M&A used to be the only way to go’: Why Seaport’s CEO opted for route to upsized $255M IPO

Cytiva (Google News)Figurate SCADA System Launched to Overcome Digital Bottlenecks During Biopharma Manufacturing - Genetic Engineering and Biotechnology News

BioWorldMoney raised by biopharma

BioWorldBiopharma money raised: Jan. 1-April 30, 2026

Endpoints NewsQ&A: Seaport CEO and CSO on learning from Karuna and the future of CNS research